Abstract
Background: Capecitabine as oral prodrug of 5-FU has shown as more convenient therapy for patients in treatment of metastatic colorectal cancer (mCRC) with similar efficacy and better safety profile than IV 5-FU. In clinical practice, dosing of capecitabine can be modified in order to control frequency and severity of adverse events. This is interim analysis of clinical trial AXIOM, where we investigated safety profile of capecitabine in treatment of mCRC, both as a monotherapy or in combined regiments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
